Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med Chin    2010, Vol. 4 Issue (3) : 264-270     DOI: 10.1007/s11684-010-0094-6
REVIEW |
Clinical significance of human papilloma virus infection in the cervical lesions
Shuang LI1, Yu-Han MENG1, Hu TING1, Jian SHEN2, Ding MA1()
1. Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2. Wuhan Central Hospital, Wuhan 430014, China
Download: PDF(118 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  

Cervical lesions have been regarded as the common and frequently occurring diseases in China. Recently, the morbidity and youth tendency of cervical cancer have gradually increased. Cervical cancer, related with human papilloma virus (HPV) infection, has been one of the severest diseases threatening health and life of women, and is an infectious disease. The universality of HPV infection in the reproductive tract should not be ignored. The well-known risk factors of HPV infection in cervical lesions consist of high-risk sexual behaviors, immunosuppression, age, contraceptive methods, the concurrent infection of other sexually transmitted diseases, etc. The variation of cervical lesions induced by HPV infection is involved in the continuous pathological process, including the subclinical, latent, and persistent infection of high risk (HR)-HPV, chronic cervicitis with abnormal results of cytological examination, cervical intraepithelial neoplasia (CIN), and cervical cancer. The outcome of patients with HPV infection is influenced by many factors, such as HPV subtype dominance, persistent HPV infection, HPV loading dose, and multiple HPV infection. Controlling HR-HPV persistent infection should be an important strategy for reducing cervical lesions.

Keywords cervical lesion      high risk-human papilloma virus      persistent infection      loading dose      cervical intraepithelial neoplasia      cervical cancer     
Corresponding Authors: MA Ding,Email:dma@tjh.tjmu.edu.cn   
Issue Date: 05 September 2010
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0094-6     OR     http://academic.hep.com.cn/fmd/EN/Y2010/V4/I3/264
1 Bekkers R L, Massuger L F, Bulten J, Melchers W J. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol , 2004, 14(2): 95–105
doi: 10.1002/rmv.416
2 Herrero R, Hildesheim A, Bratti C, Sherman M E, Hutchinson M, Morales J, Balmaceda I, Greenberg M D, Alfaro M, Burk R D, Wacholder S, Plummer M, Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst , 2000, 92(6): 464–474
doi: 10.1093/jnci/92.6.464
3 Infantolino C, Fabris P, Infantolino D, Biasin M R, Venza E, Tositti G, Minucci D. Usefulness of human papilloma virus testing in the screening of cervical cancer precursor lesions: a retrospective study in 314 cases. Eur J Obstet Gynecol Reprod Biol , 2000, 93(1): 71–75
doi: 10.1016/S0301-2115(99)00299-7
4 Sellors J W, Mahony J B, Kaczorowski J, Lytwyn A, Bangura H, Chong S, Lorincz A, Dalby D M, Janjusevic V, Keller J L. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ , 2000, 163(5): 503–508
5 Duttagupta C, Sengupta S, Roy M, Sengupta D, Chakraborty S, Bhattacharya P, Roy S, Ghosh S. Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India. Eur J Cancer Prev , 2002, 11(5): 447–456
doi: 10.1097/00008469-200210000-00007
6 Bosch F X, Lorincz A, Munoz N, Meijer C J, Shah K V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol , 2002, 55(4): 244–265
7 Deacon J M, Evans C D, Yule R, Desai M, Binns W, Taylor C, Peto J. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer , 2000, 83(11): 1565–1572
doi: 10.1054/bjoc.2000.1523
8 de Lima Soares V, de Mesquita A M, Cavalcante F G, Silva Z P, Hora V, Diedrich T, de Carvalho Silva P, de Melo P G, Dacal A R, de Carvalho E M, Feldmeier H. Sexually transmitted infections in a female population in rural north-east Brazil: prevalence, morbidity and risk factors. Trop Med Int Health , 2003, 8(7): 595–603
doi: 10.1046/j.1365-3156.2003.01078.x
9 Heard I P, Tassie J M P, Schmitz V P, Mandelbrot L, Kazatchkine M D, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol , 2000, 96(3): 403–409
doi: 10.1016/S0029-7844(00)00948-0
11 Stoler M H. Advances in cervical screening technology. Mod Pathol , 2000, 13(3): 275–284
doi: 10.1038/modpathol.3880048
12 Li L K, Dai M, Clifford G M, Yao W Q, Arslan A, Li N, Shi J F, Snijders P J, Meijer C J, Qiao Y L, Franceschi S. Human papillomavirus infection in Shenyang City, People’s Republic of China: A population-based study. Br J Cancer , 2006, 95(11): 1593–1597
doi: 10.1038/sj.bjc.6603450
13 Sellors J W, Karwalajtys T L, Kaczorowski J A, Mahony J B, Lytwyn A, Chong S, Sparrow J, Lorincz A; Survey of HPV in Older Ontario Women (SHOOW) Group. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ , 2002, 167(8): 871–873
14 Ferrera A, Velema J P, Figueroa M, Bulnes R, Toro L A, Claros J M, de Barahona O, Melchers W J. Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol , 2000, 29(5): 817–825
doi: 10.1093/ije/29.5.817
15 Walboomers J M, Jacobs M V, Manos M M, Bosch F X, Kummer J A, Shah K V, Snijders P J, Peto J, Meijer C J, Mu?oz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol , 1999, 189(1): 12–19
doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
16 Franceschi S, Herrero R, La Vecchia C. Cervical cancer screening in Europe. What next? Eur J Cancer , 2000, 36(17): 2272–2275
doi: 10.1016/S0959-8049(00)00340-3
17 Mu?oz N, Bosch F X, de Sanjosé S, Herrero R, Castellsagué X, Shah K V, Snijders P J, Meijer C J; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med , 2003, 348(6): 518–527
doi: 10.1056/NEJMoa021641
18 zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst , 2000, 92(9): 690–698
doi: 10.1093/jnci/92.9.690
19 Kulasingam S L, Hughes J P, Kiviat N B, Mao C, Weiss N S, Kuypers J M, Koutsky L A. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA , 2002, 288(14): 1749–1757
20 Liaw K L, Glass A G, Manos M M, Greer C E, Scott D R, Sherman M, Burk R D, Kurman R J, Wacholder S, Rush B B, Cadell D M, Lawler P, Tabor D, Schiffman M. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst , 1999, 91(11): 954–960
doi: 10.1093/jnci/91.11.954
21 Sherman M E, Lorincz A T, Scott D R, Wacholder S, Castle P E, Glass A G, Mielzynska-Lohnas I, Rush B B, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst , 2003, 95(1): 46–52
doi: 10.1093/jnci/95.1.46
22 Kuhn L, Denny L, Pollack A, Lorincz A, Richart R M, Wright T C. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst , 2000, 92(10): 818–825
doi: 10.1093/jnci/92.10.818
23 Peh W L, Middleton K, Christensen N, Nicholls P, Egawa K, Sotlar K, Brandsma J, Percival A, Lewis J, Liu W J, Doorbar J. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol , 2002, 76(20): 10401–10416
doi: 10.1128/JVI.76.20.10401-10416.2002
24 Woodman C B, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason T P, Young L S. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet , 2001, 357(9271): 1831–1836
25 Yang Y J, Zhao J, Xue Q L. The associativity of the different subtypes of human papilloma virus infection and cervical lesions. Zhongguo Fu Chan Ke Li Chuang Za Zhi , 2006, 7(4): 253–256 (in Chinese)
26 Ru T H, Wei L H, Wu R F, Zhou Y Q. The subtype dominance of human papillomavirus infection in the different degrees of cervical lesions. Huazhong Keji Daxue Xebao (Yixueban) , 2006, 35(6): 771–773 (in Chinese)
27 Tsai H T, Wu C H, Lai H L, Li R N, Tung Y C, Chuang H Y, Wu T N, Lin L J, Ho C K, Liu H W, Wu M T. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev , 2005, 14(11 Pt 1): 2544–2549
doi: 10.1158/1055-9965.EPI-05-0240
28 Schellekens M C, Dijkman A, Aziz M F, Siregar B, Cornain S, Kolkman-Uljee S, Peters L A, Fleuren G J. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol , 2004, 93(1): 49–53
doi: 10.1016/j.ygyno.2003.12.015
29 Deluca G D, Lucero R H, Martin de Civetta M T, Vicente L, de Gorodner O L, Schelover E, Alonso J M. Human papillomavirus genotypes in women with cervical cytological abnormalities from an area with high incidence of cervical cancer. Rev Inst Med Trop Sao Paulo , 2004, 46(1): 9–12
doi: 10.1590/S0036-46652004000100002
30 Bulk S, Berkhof J, Bulkmans N W, Zielinski G D, Rozendaal L, van Kemenade F J, Snijders P J, Meijer C J. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer , 2006, 94(1): 171–175
doi: 10.1038/sj.bjc.6602915
31 Altekruse S F, Lacey J V Jr, Brinton L A, Gravitt P E, Silverberg S G, Barnes W A Jr, Greenberg M D, Hadjimichael O C, McGowan L, Mortel R, Schwartz P E, Hildesheim A. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol , 2003, 188(3): 657–663
doi: 10.1067/mob.2003.132
32 Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiére A, Clough K, Favre M, Pouillart P, Sastre-Garau X. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol , 1998, 16(8): 2613–2619
33 Clifford G M, Smith J S, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer , 2003, 89(1): 101–105
doi: 10.1038/sj.bjc.6601024
34 Womack S D, Chirenje Z M, Gaffikin L, Blumenthal P D, McGrath J A, Chipato T, Ngwalle S, Munjoma M, Shah K V. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer , 2000, 85(2): 206–210
35 Damasus-Awatai G, Freeman-Wang T. Human papilloma virus and cervical screening. Curr Opin Obstet Gynecol , 2003, 15(6): 473–477
doi: 10.1097/00001703-200312000-00003
36 Schlecht N F, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura R A, Duarte-Franco E, Rohan T E, Ferenczy A, Villa L L, Franco E L. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA , 2001, 286(24): 3106–3114
37 Josefsson A M, Magnusson P K, Ylitalo N, S?rensen P, Qwarforth-Tubbin P, Andersen P K, Melbye M, Adami H O, Gyllensten U B. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet , 2000, 355(9222): 2189–2193
doi: 10.1016/S0140-6736(00)02401-6
38 Huang Z H, Qian D Y, Wang D, Cen J M, Shu Y H. The related research about Human papilloma viral loading dose and cervical precancerosis lesions and cervical cancer. Zhongguo Fuyou Baojian , 2006, 21(11): 1557–1559 (in Chinese)
39 Sun C A, Liu J F, Wu D M, Nieh S, Yu C P, Chu T Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gyne Obstet , 2002, 76(1): 41–47
doi: 10.1016/S0020-7292(01)00529-X
40 Sun C A, Lai H C, Chang C C, Neih S, Yu C P, Chu T Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol , 2001, 83(1): 95–99
doi: 10.1006/gyno.2001.6336
41 Schlecht N F, Trevisan A, Duarte-Franco E, Rohan T E, Ferenczy A, Villa L L, Franco E L. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer , 2003, 103(4): 519–524
doi: 10.1002/ijc.10846
42 Dalstein V, Riethmuller D, Prétet J L, Le Bail Carval K, Sautière J L, Carbillet J P, Kantelip B, Schaal J P, Mougin C. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer , 2003, 106(3): 396–403
doi: 10.1002/ijc.11222
44 Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer , 2005, 92(5): 891–894
doi: 10.1038/sj.bjc.6602436
45 Lorincz A T, Castle P E, Sherman M E, Scott D R, Glass A G, Wacholder S, Rush B B, Gravitt P E, Schussler J E, Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet , 2002, 360(9328): 228–229
doi: 10.1016/S0140-6736(02)09463-1
46 Ho G Y, Burk R D, Klein S, Kadish A S, Chang C J, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst , 1995, 87(18): 1365–1371
doi: 10.1093/jnci/87.18.1365
47 Burd E M. Human papillomavirus and cervical cancer. Clin Microbiol Rev , 2003, 16(1): 1–17
doi: 10.1128/CMR.16.1.1-17.2003
48 Lee S A, Kang D, Seo S S, Jeong J K, Yoo K Y, Jeon Y T, Kim J W, Park N H, Kang S B, Lee H P, Song Y S. Multiple HPV infection in cervical cancer screened by HPVDNAChip. Cancer Lett , 2003, 198(2): 187–192
doi: 10.1016/S0304-3835(03)00312-4
[1] Tian Wang, Yan Li, Abidan Tuerhanjiang, Wenwen Wang, Zhangying Wu, Ming Yuan, Shixuan Wang. Correlation of Twist upregulation and senescence bypass during the progression and metastasis of cervical cancer[J]. Front Med, 2014, 8(1): 106-112.
[2] Shao-Ming WANG, Jing LI, You-Lin QIAO. HPV prevalence and genotyping in the cervix of Chinese women[J]. Front Med Chin, 2010, 4(3): 259-263.
[3] Zhou-Fang XIONG MD, Wei-Hong DONG MD, Ze-Hua WANG MD, . Non-closure of the peritoneum and subcutaneous tissue at radical hysterectomy: A randomized controlled trial[J]. Front. Med., 2010, 4(1): 112-116.
[4] Zhihua LIU MD, Qing LI BM, Weihong LI BM, . Epidemiological studies of women under age 30 infected with human papillomavirus[J]. Front. Med., 2009, 3(4): 459-462.
[5] Guocheng LIU MD, Shouhua YANG MD, Zehua WANG MD, . The relationship between platelet-derived growth factor expression and angiogenesis/lymphangiogenesis in cervical cancer[J]. Front. Med., 2009, 3(4): 447-451.
[6] Yuan ZHANG MD , Xiaoyan ZHANG MM , Yanhui LI MM , Xuan DU MM , Zehua WANG MD, PhD , Hongbo WANG MD , . Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells [J]. Front. Med., 2009, 3(3): 341-346.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed